Alnylam announces fda approval of amvuttra™ (vutrisiran), an rnai therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the u.s. food and drug administration (fda) approved amvuttra™ (vutrisiran), an rnai therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hattr) amyloidosis in adults. hattr amyloidosis is a rare, inherited, rapidly progressive, and fatal diseas
ALNY Ratings Summary
ALNY Quant Ranking